Sales and Marketing

Showing 15 posts of 11524 posts found.

GlaxoSmitKline's headquarters

Revenue slump for GSK as Avandia sales stall

October 22, 2010 Sales and Marketing Avandia, GSK, GlaxoSmithKline, UK science budget, patent box, pharma's 2010 results, pharma's Q3 results

GlaxoSmithKline has posted a third quarter loss after sales of its troubled diabetes drug Avandia and pandemic influenza products fell. …

Lilly suspends late-stage trials of diabetes drug Protege

October 22, 2010 Research and Development, Sales and Marketing MacroGenics, Protege, diabetes, lilly, type I diabetes

Eli Lilly and its partner MacroGenics have suspended phase III trials of their investigational type I diabetes drug Protege after …

Anna Protopapas to lead Takeda’s global business development unit

October 21, 2010 Sales and Marketing Anna Protopapas, Japanese pharma company, Takeda, appointment, sales and marketing

Takeda has set up a new global business development unit within its US subsidiary to oversee mergers, acquisitions and other …

Novartis posts strong Q3 results

October 21, 2010 Sales and Marketing 2010 financials, Novartis, Novartis quarterly results, Q3, pharma sales

Novartis has posted double digit growth for the third quarter following a strong showing by a number of recently launched …

FDA approves Boehringer’s Pradaxa

October 20, 2010 Sales and Marketing Boehringer, Pradaxa, atrial fibrilation

Boehringer Ingelheim’s Pradaxa has stolen a march over its rivals by being the first new oral anticoagulant to reach the …

FDA warns of bisphosphonates fracture risk

October 20, 2010 Sales and Marketing Boniva, Fosamax, Reclast, actonel, bisphosphonates, osteoporosis

The FDA has ordered a label change for a number of osteoporosis drugs after concerns their long-term use raises the …
Pharma association the ABPI

NICE needs narrower focus, says ABPI

October 20, 2010 Sales and Marketing ABPI, NICE, value

NICE’s remit should be changed to give it a greater focus on the value of innovation, according to UK pharma …

Apixaban trial for ACS abandoned

October 20, 2010 Sales and Marketing ACS, BMS, Pfizer, apixaban

  Pfizer and Bristol-Myers Squibb have halted a trial of their heart drug apixaban after signs of increased risk of …
Dr Ben Goldacre

Dr Ben Goldacre: “This is a very broken system”

October 19, 2010 Medical Communications, Research and Development, Sales and Marketing Bad Science, Ben Goldacre, industry reputation, trial data

The pharma industry has its fair share of critics, but unfortunately for everybody, many are easy to dismiss – shrill, …

Trial shows long-term benefits of Novartis’ Aclasta

October 18, 2010 Research and Development, Sales and Marketing Novartis, aclasta, osteoporosis

Novartis has published new data at the annual meeting of the American Society for Bone and Mineral Research in Toronto …
2fe094c

IDEA Pharma appoints Tony Akiwumi

October 18, 2010 Sales and Marketing Go-To-Market Strategy, IDEA Pharma, IDEAtion, Phase II, appointment, sales and marketing

Tony Akiwumi has joined Idea Pharma as director of client value, moving to the strategic marketing consultancy from Quintiles.He will lead …

In with the ‘new’: A leaner, fitter biosciences sector – 2010

October 18, 2010 Sales and Marketing Kinapse, White paper

The biosciences sector has witnessed numerous challenges during recent years, as the global economic downturn has adversely impacted sector liquidity …
Images of a normal brain and an Alzheimer's brain

Alzheimer’s disease

October 16, 2010 Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, Elan, J&J, JJ, Pfizer, lilly, pharmaceutical

In 1906 a psychiatrist working in a Frankfurt asylum became fascinated by the unnamed illness suffered by one of his …

Discovery Innovation – Productive Partnering For Shared Success

October 15, 2010 Sales and Marketing Kinapse, White paper

Partnering is an integral feature within today’s pharmaceutical industry. While the conventional wisdom suggests that Phase II represents the optimum …
Swiss pharma company Roche

Roche revenue depressed by plummeting Tamiflu sales

October 15, 2010 Sales and Marketing 2010 financials, Q3, Roche

Roche suffered a 3% drop in group revenue in the third quarter as sales of its Tamiflu plummeted by 90 …
The Gateway to Local Adoption Series

Latest content